Tracking CLL cells with aberrations in the TP53 gene using
scRNA-seq in relapsed/refractory patients.

a 2023

Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ; Kamila RÉBLOVÁ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ et al.

Základní údaje

Originální název

Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.

Autoři

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ ; Kamila RÉBLOVÁ ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ; Michael DOUBEK; Jitka MALČÍKOVÁ ; Šárka PAVLOVÁ ; Jana KOTAŠKOVÁ a Šárka POSPÍŠILOVÁ

Vydání

XX. International Workshop on CLL (iwCLL 2023), Boston, USA, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/23:00132844

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

TP53 gene aberrations; CCL; resistance

Štítky

NÚVR_CEITEC, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 12. 2025 13:13, Mgr. Petra Trembecká, Ph.D.

Anotace

V originále

TP53 gene aberrations (mutation and/or deletion 17p) are the most important adverse prognostic and predictive markers in CLL • Low-burden TP53 mutations are often detectable in CLL cells prior to the therapy and expand upon the selective pressure of chemoimmunotherapy • Other genomic alterations accompany aberrations in the TP53 gene • Bulk analysis (such as whole genome/exome sequencing or genomic array) cannot precisely determine the co-occurrence of abnormalities in individual cells • Expression profiles of cells bearing TP53 mutation are altered and may be distinguished from expression profiles of unaffected cells using single-cell RNA sequencing (scRNA-seq). We aimed to explore the possibility to identify and characterize populations of CLL cells resistant to treatment and causing refractoriness in samples from patients with disease relapse. We tried to trace back the refractory cells in samples prior to the therapy using scRNA-seq in patients with TP53 mutations

Návaznosti

MUNI/A/1224/2022, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X

NU20-08-00314, projekt VaV

Název: Single cell analýza: moderní nástroj pro studium klonální evoluce u pacientů s chronickou lymfocytární leukémií s vysokým rizikem (Akronym: Single cell analysis of CLL cells)

Investor: Ministerstvo zdravotnictví ČR, Single cell analysis: a modern tool to study clonal evolution in high-risk patients with chronic lymphocytic leukemia, Podprogram 1 - standardní

Přiložené soubory

iwCLL2023_Navrkalova_poster_SCA.pdf

Citovat

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ; Kamila RÉBLOVÁ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ; Michael DOUBEK; Jitka MALČÍKOVÁ; Šárka PAVLOVÁ; Jana KOTAŠKOVÁ a Šárka POSPÍŠILOVÁ. Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.

@proceedings{2357961,
   author = {Navrkalová, Veronika and Kurucová, Terézia and Réblová, Kamila and Bohúnová, Michaela and Plevová, Karla and Doubek, Michael and Malčíková, Jitka and Pavlová, Šárka and Kotašková, Jana and Pospíšilová, Šárka},
   booktitle = {XX. International Workshop on CLL (iwCLL 2023), Boston, USA},
   keywords = {TP53 gene aberrations; CCL; resistance},
   language = {eng},
   title = {Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.},
   url = {https://iwcll2023.org/},
   year = {2023}
}

TY  - CONF
ID  - 2357961
AU  - Navrkalová, Veronika - Kurucová, Terézia - Réblová, Kamila - Bohúnová, Michaela - Plevová, Karla - Doubek, Michael - Malčíková, Jitka - Pavlová, Šárka - Kotašková, Jana - Pospíšilová, Šárka
PY  - 2023
TI  - Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.
KW  - TP53 gene aberrations
KW  - CCL
KW  - resistance
UR  - https://iwcll2023.org/
N2  - TP53 gene aberrations (mutation and/or deletion 17p) are the most important adverse prognostic and predictive markers in CLL • Low-burden TP53 mutations are often detectable in CLL cells prior to the therapy and expand upon the selective pressure of chemoimmunotherapy • Other genomic alterations accompany aberrations in the TP53 gene • Bulk analysis (such as whole genome/exome sequencing or genomic array) cannot precisely determine the co-occurrence of abnormalities in individual cells • Expression profiles of cells bearing TP53 mutation are altered and may be distinguished from expression profiles of unaffected cells using single-cell RNA sequencing (scRNA-seq). We aimed to explore the possibility to identify and characterize populations of CLL cells resistant to treatment and causing refractoriness in samples from patients with disease relapse. We tried to trace back the refractory cells in samples prior to the therapy using scRNA-seq in patients with TP53 mutations
ER  -

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ; Kamila RÉBLOVÁ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ; Michael DOUBEK; Jitka MALČÍKOVÁ; Šárka PAVLOVÁ; Jana KOTAŠKOVÁ a Šárka POSPÍŠILOVÁ. Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients. In \textit{XX. International Workshop on CLL (iwCLL 2023), Boston, USA}. 2023.

Přehled o publikaci